Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

Community delivery of medication of transport services, community health workers, all of these services are currently still impacted", Christine Stegling, deputy executive director of UNAIDS, told ...

Q4 2024 Earnings Conference Call February 7, 2025 3:00 AM ETCompany ParticipantsNicolas Hieronimus - CEOChristophe Babule ...

On Wednesday, Recursion announced favorable efficacy data in the Phase II trial for REC-994, the company’s lead AI-derived candidate ... University of Utah in the lab of Dean Li, MD, PhD.

KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present ...

But another finding also caught the investigators’ attention: Laboratory data available from ... anemia in all women of reproductive age could lead to risk reduction and improved maternal ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...